What Pfizer's latest 10-Q says: 9 signals

Pfizer filed its latest 10-Q with the SEC on Aug 4, 2026. It discusses automation investment, goodwill impairment and joint venture.

Public (PFE)Pharmaceutical Manufacturing10,000+ employeespfizer.comLinkedIn

Filed: Aug 4, 2026
Filings: 2
Signals: 14

10-Q · latest 10

What Pfizer's 10-Q filings say

10-Q
Filed Aug 4, 2026 · 9 signals
SEC EDGAR
- Restructuring chargeNegative
  Pfizer launches major restructuring to save $2.5B, spending $6B on implementation through 2029.
  The company announced two large-scale programs to reduce costs, one targeting $1B in savings via technology and simplification, and another targeting $1.5B in manufacturing optimization.
  $6B
  one-time costs to achieve $2.5 billion in savings from two restructuring programs through 2029
  technology
- Margin pressureNegative
  Pfizer swings from a $3.0B Q2 profit in 2025 to a $653M pre-tax loss in Q2 2026.
  The company reported a significant profitability decline, moving from substantial income to a loss year-over-year.
  $-653M
  Loss from continuing operations before provision/(benefit) for taxes on income/(loss) in Q2 2026
- Joint venturePositive
  Pfizer forms $10.5B oncology JV with Innovent for 12 new cancer drugs
  Pfizer is co-developing and co-commercializing a portfolio of 12 cancer medicines, creating significant R&D and commercialization activity.
  $10.5B
  Total potential value of collaboration agreement with Innovent, including $650M upfront and $9.85B in milestones.
  antibody-drug conjugates (ADCs)multi-specific antibodiesInnovent
- Automation investmentPositive
  Pfizer targets technology and simplification for $1B in cost savings.
  The company is explicitly funding technology-driven productivity enhancements to achieve $1 billion in net cost savings, indicating a clear budget and mandate for solutions that can automate and simplify commercial, R&D, and administrative functions.
  $1B
  Anticipated net cost savings driven by technology and simplification efforts.
  technology
- Platform strategyNeutral
  Pfizer launches $6B transformation to drive $2.5B in savings via technology & simplification
  Facing a quarterly loss, Pfizer is investing $6B in enterprise-wide restructuring focused on technology-driven productivity and manufacturing efficiency.
  $6B
  Total one-time costs ($2B + $4B) to achieve $2.5B in annual savings through restructuring and manufacturing optimization programs through 2029.
  technology
- Goodwill impairmentNegative
  Intangible asset impairment charges cited as a primary driver of Pfizer's Q2 2026 loss.
  The company's significant quarterly loss was directly attributed to charges for writing down the value of intangible assets.
- Manufacturing issueNegative
  Pfizer launches program to cut $1.5B in manufacturing costs by 2029.
  Pfizer is addressing high cost of goods sold (COGS) by initiating a multi-year program focused on network structure changes and operational efficiencies.
  $1.5B
  Anticipated savings from a program to reduce cost of goods sold through 2029.
- Litigation materialNegative
  Charges for 'certain legal matters' contribute significantly to Pfizer's quarterly loss.
  The company's swing to a $653 million pre-tax loss was partly caused by unspecified but material charges related to legal issues.
10-Q
Filed May 5, 2026 · 5 signals
SEC EDGAR
- RestructuringNeutral
  Pfizer's acquisition of Metsera in Nov 2025 signals major integration projects in 2026.
  The recent acquisition of Metsera is a significant business development initiative that will require integrating the new entity's operations, data, and systems.
- Restructuring chargeNeutral
  Pfizer integrating Metsera acquisition from Nov 2025, incurring acquisition-related costs.
  Following its recent acquisition of Metsera, Pfizer is incurring acquisition-related costs.

Showing 10 of 14 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Pfizer earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call date	Period	What the company said
Nov 4, 2025	Q3 FY2025	Driving $7.7B in cost savings by 2027 through major realignment programThe company is executing a massive cost-cutting and efficiency program, targeting $4.5B by the end of 2025 and $7.7B total by 2027. This creates opportunities for vendors offering solutions that improve productivity, automate processes, and reduce operational expenses.
Nov 4, 2025	Q3 FY2025	Committing to multi-year investment in US manufacturing facilitiesAs part of a new agreement with the U.S. government, Pfizer is committed to investing in and building out its domestic manufacturing capacity over a three-year period, creating significant opportunities for industrial equipment, automation, and construction vendors.
Nov 4, 2025	Q3 FY2025	Investing in AI and digital tools to boost R&D productivityThe CFO explicitly stated a strategy to use digital tools and AI to improve R&D productivity, even as overall R&D spend is optimized. This is a direct signal for AI/ML platform vendors, data analytics firms, and cloud providers focused on the life sciences R&D process.
Nov 4, 2025	Q3 FY2025	Targeting $7.7B in savings by 2027 via major efficiency programA massive, multi-year cost realignment program is underway to drive operational efficiencies. Achieving this goal will require significant investment in new technologies, process automation, and consulting services to optimize the business.
Nov 4, 2025	Q3 FY2025	Pursuing $4.9B acquisition of Metsera, creating major integration needsThe planned multi-billion dollar acquisition of Metsera will create significant post-merger integration challenges, opening doors for vendors specializing in IT systems consolidation, data migration, and process alignment.
Nov 4, 2025	Q3 FY2025	Facing headwinds activating a difficult patient population for RSV vaccineThe CEO acknowledged challenges in reaching and activating the target population for its Abrysvo RSV vaccine in the U.S. This pain point creates an opportunity for vendors specializing in patient engagement, targeted digital marketing, healthcare data analytics, and consumer health campaigns.

Signal API · MCP

Track Pfizer with the Signal API

One POST /v1/companies/enrich call with pfizer.com returns Pfizer 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"pfizer.com","signal_types":["sec-10q"],"limit":20}'

Same industry

Questions about Pfizer 10-Q

When did Pfizer file its latest 10-Q?

Pfizer filed its latest 10-Q on Aug 4, 2026. The one before it was filed on May 5, 2026.

What did Pfizer disclose in its latest 10-Q?

From the filing dated Aug 4, 2026: Pfizer launches major restructuring to save $2.5B, spending $6B on implementation through 2029.

What did Pfizer say on its recent earnings calls?

Q3 FY2025: Driving $7.7B in cost savings by 2027 through major realignment program (dated Nov 4, 2025).

Where can I read Pfizer's 10-Q filing?

The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/78003/000007800326000095/pfe-20260628.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of Sep 30, 2026.

How this data is built →Get it from the Signal API →

What Pfizer's latest 10-Q says: 9 signals

What Pfizer's 10-Q filings say

Pfizer earnings headlines

Track Pfizer with the Signal API

10-Q at related companies

Questions about Pfizer 10-Q